Global Study of Del-desiran for the Treatment of DM1
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
Sponsor: Avidity Biosciences, Inc.
This PHASE3 trial investigates DM1 and Dystrophy Myotonic and is currently ongoing. Avidity Biosciences, Inc. leads this study, which shows 15 recorded versions since 2024 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
15 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2025 — Aug 2025 [monthly]
Recruiting PHASE3
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE3
▶ Show 10 earlier versions
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE3
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE3
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE3
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE3
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE3
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE3
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE3
First recorded
May 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Avidity Biosciences, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarhus N, Denmark, Aomori, Japan, Baltimore, United States, Boston, United States, Cincinnati, United States, Columbus, United States, Copenhagen, Denmark, Denver, United States, Donostia / San Sebastian, Spain, Durham, United States and 22 more location s